11 Best High Short Interest Stocks With Biggest Upside Potential

分组1 - Sherry Paul from Morgan Stanley discusses market volatility, emphasizing it as a normal part of investing and indicating a shift from the 'Magnificent Seven' to 'magnificent thematics' such as AI automation and innovation [1][2] - The MAG7 companies are evolving into diversified holding companies, with traditional sector labels becoming distorted as tech firms venture into new industries [2] - Paul recommends an equal-weight approach for ETF investors to avoid over-concentration in mega-cap stocks and suggests focusing on the remaining 473 stocks in the S&P 500 for investment opportunities [2] 分组2 - Apellis Pharmaceuticals Inc. (NASDAQ:APLS) has an average upside potential of 47.33%, with Bank of America upgrading its rating to Buy, citing undervalued prospects for its drug Empaveli in treating rare kidney diseases [7][8] - Wells Fargo has reduced its price target for Apellis to $26 from $29, reflecting a slower-than-expected commercial ramp for Empaveli, while cutting revenue estimates for 2026-2030 by 20% to 50% [9][10] - Vera Therapeutics Inc. (NASDAQ:VERA) shows an average upside potential of 55.09%, with Bank of America raising its price target from $48 to $66 due to increased revenue forecasts for its lead drug [11][12] - Goldman Sachs and JPMorgan have also raised their price targets for Vera Therapeutics, reflecting a broader market potential and positive developments in its drug pipeline [12][13]